2. E-source http: // www.10mkb.ru. Russian (Электронный ресурс http: // www.10mkb.ru).

3. Muromceva G.A. et al. Prevalence of risk factors for non-infectious diseases in Russian population in 2012–2013 yy. The results of the study ESSE RF. Kardiovaskuljarnaja terapiia i profilaktika. 2014;13(6):4–11. Russian (Муромцева Г.А. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4–11).

4. Maslennikova G.Ya., Boycov S.A., Oganov R.G., Aksel'rod S.V.,Esin P.E. Non-infectious diseases as a global problem for healthcare system and a role of WHO in its overcoming. Profilakticheskaya medicina. 2015;1:9–13. Russian (Масленникова Г.Я., Бойцов С.А., Оганов Р.Г.,Аксельрод С.В., Есин П.Е. Неинфекционные заболевания как глобальная проблема здравоохранения, роль ВОЗ в ее решении. Профилактическая медицина. 2015;1:9–13.

5. Mozaffarian D., Fahimi S., Singh G.M. et al. Global Burden of Diseases Nutrition and Chronic Diseases Expert Group. Global sodium consumption and death from cardiovascular causes. N Engl J Med. 2014;371(7):624−634.

6. James W.P.T., Jackson-Leach R., Mhurdu C.N. et al Overweight and Obesity. In Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors: eds. Ezzati M, Lopez AD, Rodgers A, Murray CJL. WHO, Geneva, 2003.

7. Ligibel J.A. et al. American Society of Clinical Oncology position statement on obesity and cancer. J. Clin. Oncol. 2014; 32(31): 3568–3574.

8. World Health Organization Media Centre. Obesity and overweight. Fact sheet no Geneva: World Health Organization; 2013.

9. Kramer C.K., Zinman B., Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann. Int. Med. 2013;159(11): 758–769.

10. Jiao L. et al. Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes & Control. 2010;21(8):1305–1314.

11. Jungheim E.S. et al. Obesity and reproductive function. Obstetrics and gynecology clinics of North America. 2012;39(4):479–493.

12. Shlyahto E.V., Nedogoda S.V., Konradi A.O. Diagnosis, treatment and prevention of obesity and associated diseases (national clinical guidelines). Saint Petersburg, 2017. 164 p. Russian (Шляхто Е.В., Недогода С.В., Конради А.О. Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний (национальные клинические рекомендации). СПб., 2017. 164 с.).

13. Kalinchenko S.Ju., Tishova Yu.A., Tyuzikov I.A., Vorslov L.O. Obesity and metabolic syndrome in men. М.: Prakticheskaya medicina, 2014. 128 p. Russian (Калиниченко С.Ю., Тишова Ю.А, Тюзиков И.А., Ворслов Л.О. Ожирение и метаболический синдром у мужчин. М.: Практическая медицина, 2014. 128 с.).

14. Booth A., Magnuson A., Fouts J., Foster M.T. Adipose tissue: an endocrine organ playing a role in metabolic regulation. Horm Mol Biol Clin Investig. 2016;26(1):25–42.

15. Coles C.A. Adipokines in Healthy Skeletal Muscle and Metabolic Disease. Adv Exp Med Biol. 2016;900:133–160.

16. Luo L., Liu M. Adipose tissue in control of metabolism. J Endocrinol. 2016;231(3):R77–R99.

17. Villarroya F., Cereijo R., Villarroya J., Giralt M. Brown adipose tissue as a secretory organ. Nat Rev Endocrinol. 2017;13(1):26–35.

18. Kalinchenko S.Yu., Tyuzikov I.A., Vorslov L.O., Tishova Yu.A., Grekov E.A., Fomin A.M. Obesity (insulin resistance) and infertility are two sides of one coin: pathogenetic interactions and opportunities for modern pharmacotherapy. Consilium Medicum. 2015;17(4):51–58. Russian (Калинченко С.Ю., Тюзиков И.А., Ворслов Л.О., Тишова Ю.А., Греков Е.А., Фомин А.М. Ожирение (инсулинорезистентность) и бесплодие – две стороны одной медали: патогенетические взаимодействия и возможности современной фармакотерапии. Consilium Medicum. 2015;17(4):51–58).

19. Roncavi D.A.K., van R.L.R. Promotion of human adipocite precursor replication by 17 bestradiol in culture. J Clin Invest 1977;62:503–508.

20. Dobs A.S., Bachorik P.S., Arver S. et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab 2001;86(3):1026–1033.

21. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89(6):2548–2556.

22. Kalinchenko S.Ju., Tyuzikov I.A., Vorslov L.O., Tishova Yu.A. Obesity, insulin resistance and reproductive men’s health: pathogenetic interactions and modern pharmacotherapy. Effektivnaya farmakoterapiia. Urologiia i nefrologiia. 2015;27: 66–79. Russian (Калинченко С.Ю.,Тюзиков И.А., Ворслов Л.О., Тишова Ю.А. Ожирение, инсулинорезистентность и репродуктивное здоровье мужчины: патогенетические взаимодействия и современная патогенетическая фармакотерапия. Эффективная фармакотерапия. Урология и нефрология. 2015;27: 66–79).

23. Mohler E.R. 3rd, Ellenberg S.S., Lewis C.E. et al. The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. J Clin Endocrinol. Metab. 2018;103(2):681–688.

24. Saad F. Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency (Hypogonadism). Adv Exp Med Biol. 2017;1043:527–558.

25. Тюзиков И.А., Калинченко С.Ю., Ворслов Л.О., Тишова Ю.А. Витамин D, мужское здоровье и мужская репродукция. Андрология и генитальная хирургия. 2013;4:36–44.

26. Kalyani R.R., Dobs A.S. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes. 2007;14(3):226–234.

27. Schaffer J.E. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003;14(3):281–287.

28. Irwin D.E., Milsom I., Hunskaar S. et al. Population Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study, 04 October 2006 Eur Urol. 2006;50(6):1306–1315.

29. Kristal A.R., Arnold K.B., Schenk J.M. et al Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial J Urol. 2007; 177: 1395–1400.

30. Gacci M., Corona G., Vignozzi L., Salvi M., Serni S., De Nunzio C. et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analisys. BJU Int 2015;115(1):24–31.

31. Kaplan S., Fisch H., Berriman S.J. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms, sexual dysfunction, and components of the metabolic syndrome J Urol. 2007;177(Suppl):497–98.

32. Cinar A., Hall S.A., Link C.L. et al. Cluster analysis and lower urinary tract symptoms in men: fi ndings from the Boston Area Community Health Survey. BJU Int. 2008;101:1247, 56.

33. Desgrandchamps F., Haab F., Coloby P., Slama A., Gaudin A.F. Instant 2006: cardiometabolic markers in subjects with lower urinary tract symptoms in the French general population Eur Urol Suppl. 2008;7:130, Abstract 237.

34. Kim G.W., Doo S.W., Yang W.J., Song Y.S. Effects of obesity on prostate volume and lower urinary tract symptoms in Korean men. Korean J Urol. 2010;51:344–347.

35. Chu K.F., Rotker K., Ellsworth P. The impact of obesity on benign and malignant urological conditions. Postgrad Med. 2013;125(4):53–69.

36. Lee R.K., Chung D., Chughtai B., Te A.E., Kaplan S.A. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms BJU. 2012;110(4): 540–545.

37. Parsons J.K., Sarma A.V., Mc Vary K., Wei J.T. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol 2009;182 (6 suppl):27–31.

38. Pashootan P., Ploussard G., Cocaul Aю, Gouvello Aю, Desgrandchamps F. Association between metabolic syndrome and severity lower urinary tract symptoms (LUTS): an observation study in a 4666 European men cohort. BJU Int 2015;116(1):124–130.

39. Kseneva S.I., Yurmazov Z.A., Udut V.V. An influence of non-drug correction of metabolic syndrome on the prostate in young men. Evrazijskij Sojuz Uchenyh. 2016;2-2(23):64–66. Russian (Ксенева С.И., Юрмазов З.А., Удут В.В. Влияние немедикаментозной коррекции метаболического синдрома на состояние предстательной железы у пациентов молодого возраста. Евразийский союз ученых. 2016;2–2(23):64–66).

40. Khoo J., Piantadosi C., Worthley S., Wittert G.A. Effects of a low-energy diet on sexual function and lower urinarytract symptoms in obese men. Int J Obes 2010;34:1396–1403.

41. Parsons J.K., Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. EurUrol 2008;53:1228–1235.

42. Jung J.H., Ahn S.V., Song J.M. et al. Obesity as a Risk Factor for Prostatic Enlargement: A Retrospective Cohort Study in Korea. Int Neurourol J. 2016;20(4):321–328.

43. Zhang X., Zong X., Liu Y. et al. Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol. Int. 2014;93:214–219.

44. Dahle S.E., Chokkalingam A.P., Gao Y.T. et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168(2):599–604.

45. Fong Y.K., Milani S., Djavan B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Curr Opin Urol. 2005;15(1): 5–38.

46. Ganpule A.P., Desai M.R., Desai M.M. Natural history of lower urinary tract symptoms: Preliminary report from a community-based Indian study. BJU Int. 2004;94:332–334.

47. Patel N.D., Parsons J.K. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol. 2014;30(2):170–176.

48. Tyagi P., Motley S.S., Koyama T. et al. Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients. Prostate. 2018;78(1):17–24.

49. Rasin M.S. Chronic inflammation and insulin resistance in pathogenesis of benign prostatic hyperplasia. Eksperimental'naya i klinicheskaya urologiya. 2016;1: 52–56. Russian (Расин М.С. Хроническое воспаление и инсулинорезистентность в патогенезе доброкачественной гиперплазии предстательной железы. Экспериментальная и клиническая урология. 2016;1: 52–56).

50. Bastard J.-P., Maachi M., Lagathu C. et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006;17(1):4–12.

51. De Nunzio C., Kramer G., Marberger M. et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur. Urol. 2011;60(1):106–117.

52. De Nunzio C., Aronson W., Freedland S.J. et al. The correlation between metabolic syndrome and prostatic diseases. Eur. Urol. 2012;61(3):560–570.

53. Shenk J.M., Kristal A.P., Neuhouser M.L. et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am. J. Epidemiol. 2010;171(5):571–582.

54. Gacci M., Vignozzi L., Sebastianelli A. et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 2013;16(1):101–106.

55. He Q., Wang Z., Liu G. et al. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational risks. Prostate Cancer Prostatic Dis 2016; 19(1):7–13.

56. Ozer K., Horsanali M.O., Gorgel S.N. et al. Association between benign prostatic hyperplasia and neutrophil-lymphocyte ratio, an indicator of inflammation and metabolic syndrome. Urol. Int. 2016.

57. Vignozzi L., Gacci M., Cellai I. et al. Fat boost, while androgene receptor activation counteracts BPH-associated prostate inflammation. Prostate. 2013;73(8):789–800.

58. Robert G., Descazeaud A., Nicolaïew N. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate. 2009;69:1774–1780.

59. Rohrmann S., De Marzo A.M., Smith E. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate. 2005;62:27–33.

60. Penna G., Fibbi B., Amuchastegui S. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009;69:480–493.

61. Fibbi B., Penna G., Morelli A. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int. J. Androl. 2010;33:475–488.

62. Protopsaltis I., Ploumidis A., Sergentanis T.N., Constantoulakis P., Tzirogiannis K., Kyprianidou C. et al. Linking pre-diabetes with benign prostatic hyperplasia. IGFBP-3: a conductor of benign prostatic hyperplasia development orchestra? PloS One. 2013;8(12):e81411.

63. Cantiello F., Cicione A., Salonia A. et al. Metabolic syndrome correlates with peri-urethral fibrosis secondary to chronic prostate inflammation: evidence of a link in a cohort of patients undergoing radical prostatectomy. Int J Urol. 2014; 21(3): 264–269.

64. Morelli A., Comeglio P., Filippi S. et al. Mechanism of action of phosphodiesterase 5 inhibition on metabolic syndrome-associated prostate alteration: an experimental study in the rabbit. Prostate 2013;73(4):428–441.